An overwhelming majority of the audience at an RSNA special focus session voted in favor of keeping up the efforts to get FDA approval for the use of contrast ultrasound for general radiology applications.
An overwhelming majority of the audience at an RSNA special focus session voted in favor of keeping up the efforts to get FDA approval for the use of contrast ultrasound for general radiology applications.
When moderator Peter N. Burns, Ph.D., a professor in the department of medical biophysics at the University of Toronto, asked those in the 200-plus crowd to raise their hands if they supported continued pursuit of ultrasound contrast, all but a dozen physicians shot their hands up. When Burns asked to see the hands of those who thought contrast should be let go, only one went up.
A panel composed of Burns and Drs. Stephanie R. Wilson from Canada, Luigi Solbiati from Italy, and Myron A. Pozniak from Madison, WI, discussed the regulatory approval status for contrast-enhanced sonography around the world, its clinical applications, and the arguments in favor of and against the technique.
After the panel discussion and the straw poll, members of the audience shared commentaries. Most agreed that the technique is useful and valuable in multiple imaging subspecialties: musculoskeletal, ob/gyn, cardiovascular, interventional radiology, and others. They also agreed, however, that the reimbursement landscape in the U.S. overwhelmingly favors CT and MR imaging over sonography, which is still considered a time-consuming and operator-dependent modality.
Many said the choice is inevitable. But it could also be harmful to radiology.
"The FDA does not get any benefit from saying 'yes' and having a complication or something negative occur. And there is no cost to them to saying 'no.' The constituency for this is outside radiology," an audience member said. "But then everybody else will end up doing ultrasound, and in the future, radiologists will be relegated to the sidelines by other subspecialists, who will be doing diagnostic studies using contrast ultrasound."
For more online information, visit Diagnostic Imaging's RSNA Webcast.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.